Gapping up
In reaction to strong earnings/guidance: NTWK +28.1%, AVNW +15.5%, (disclosed earnings in 10-Q before the close), MOSY +15.5%, HDP +14.6%,KGC +10.5%, CDE +9.6%, EXPE +8.6%, QTWO +6.8%, LC +6.8%, AEM+6.6%, SKX +6%, CSCO +5.7%, (increases qtrly dividend to $0.26 from $0.21/share; increases repurchase program ), CSRA +4.5%, RPD +4.3%,HUBS +3.3%, TSLA +3.2%, WWAV +2.9%, OZM +2.5%, ORLY +2.3%, VG+2.2%, NOK +2.1%, NOK +2.1%, BWA +2.1%, BKFS +1.7%, EFX +1.6%,ACOR +1.6%, WWE +1.5%, CCE +1.3%, FNF +1.2%, ALLE +1.1%, NNN+1.1%, LPX +1%, PJT +1%
Select metals/mining stocks trading higher: DRD +12.7%, SSRI +10.9%,AUY +10.7%, AUY +10.7%, MUX +9.5%, GFI +9.4%, KGC +8.9%, IAG +8.7%,HMY +8.4%, GG +8.4%, PAAS +8.3%, SLW +7.6%, ABX +7.3%, NEM +7%, HL+6.2%, GDX +5.3%, GOLD +3.1%, GLD +3%, SLV +2.1%
Other news: CUI +9.3% (announces award of first purchase order for delivery of its GasPT Technology), PCLN +3.1% (in symp with EXPE), AZN+1% (granted orphan designation by the FDA for its humanized affinity-optimized, afucosylated immunoglobulin G1 kappa monoclonal antibody against CD19 )
Analyst comments: ASNA +1.9% (upgraded to Neutral from Sell at Goldman)
In reaction to strong earnings/guidance: NTWK +28.1%, AVNW +15.5%, (disclosed earnings in 10-Q before the close), MOSY +15.5%, HDP +14.6%,KGC +10.5%, CDE +9.6%, EXPE +8.6%, QTWO +6.8%, LC +6.8%, AEM+6.6%, SKX +6%, CSCO +5.7%, (increases qtrly dividend to $0.26 from $0.21/share; increases repurchase program ), CSRA +4.5%, RPD +4.3%,HUBS +3.3%, TSLA +3.2%, WWAV +2.9%, OZM +2.5%, ORLY +2.3%, VG+2.2%, NOK +2.1%, NOK +2.1%, BWA +2.1%, BKFS +1.7%, EFX +1.6%,ACOR +1.6%, WWE +1.5%, CCE +1.3%, FNF +1.2%, ALLE +1.1%, NNN+1.1%, LPX +1%, PJT +1%
Select metals/mining stocks trading higher: DRD +12.7%, SSRI +10.9%,AUY +10.7%, AUY +10.7%, MUX +9.5%, GFI +9.4%, KGC +8.9%, IAG +8.7%,HMY +8.4%, GG +8.4%, PAAS +8.3%, SLW +7.6%, ABX +7.3%, NEM +7%, HL+6.2%, GDX +5.3%, GOLD +3.1%, GLD +3%, SLV +2.1%
Other news: CUI +9.3% (announces award of first purchase order for delivery of its GasPT Technology), PCLN +3.1% (in symp with EXPE), AZN+1% (granted orphan designation by the FDA for its humanized affinity-optimized, afucosylated immunoglobulin G1 kappa monoclonal antibody against CD19 )
Analyst comments: ASNA +1.9% (upgraded to Neutral from Sell at Goldman)